Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
9.66
+0.30 (3.21%)
At close: May 12, 2025, 4:00 PM
9.62
-0.04 (-0.41%)
After-hours: May 12, 2025, 6:45 PM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$285,586
Profits / Employee
-$695,164
Market Cap
527.41M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
STOK News
- 5 weeks ago - Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - Stoke Therapeutics Stock Slips as CEO Steps Down - Investopedia
- 7 weeks ago - Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Business Wire
- 7 weeks ago - Stoke Therapeutics Announces CEO Transition - Business Wire
- 2 months ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - Market Watch
- 2 months ago - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Business Wire
- 3 months ago - Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha